RESUMO
Neurofibromatosis type 2 (NF2) is a genetic disorder with bilateral vestibular schwannomas (VS) as the most frequent manifestation. Merlin, the NF2 tumor suppressor, was identified as a negative regulator of mammalian target of rapamycin complex 1. Pre-clinical data in mice showed that mTORC1 inhibition delayed growth of NF2-schwannomas. We conducted a prospective single-institution open-label phase II study to evaluate the effects of everolimus in ten NF2 patients with progressive VS. Drug activity was monitored every 3 months. Everolimus was administered orally for 12 months and, if the decrease in tumor volume was >20 % from baseline, treatment was continued for 12 additional months. Other patients stopped when completed 12 months of everolimus but were allowed to resume treatment when VS volume was >20 % during 1 year follow-up. Nine patients were evaluable. Safety was evaluated using CTCAE 3.0 criteria. After 12 months of everolimus, no reduction in volume ≥20 % was observed. Four patients had progressive disease, and five patients had stable disease with a median annual growth rate decreasing from 67 %/year before treatment to 0.5 %/year during treatment. In these patients, tumor growth resumed within 3-6 months after treatment discontinuation. Everolimus was then reintroduced and VS decreased by a median 6.8 % at 24 months. Time to tumor progression increased threefold from 4.2 months before treatment to > 12 months. Hearing was stable under treatment. The safety of everolimus was manageable. Although the primary endpoint was not reached, further studies are required to confirm the potential for stabilization of everolimus.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Everolimo/uso terapêutico , Neurilemoma/tratamento farmacológico , Neurofibromatose 2/tratamento farmacológico , Doenças do Nervo Vestibulococlear/tratamento farmacológico , Adolescente , Adulto , Antineoplásicos/efeitos adversos , Biomarcadores Tumorais/metabolismo , Neoplasias dos Nervos Cranianos/patologia , Neoplasias dos Nervos Cranianos/fisiopatologia , Progressão da Doença , Intervalo Livre de Doença , Everolimo/efeitos adversos , Feminino , Seguimentos , Humanos , Masculino , Alvo Mecanístico do Complexo 1 de Rapamicina , Complexos Multiproteicos/antagonistas & inibidores , Complexos Multiproteicos/metabolismo , Neurilemoma/patologia , Neurilemoma/fisiopatologia , Neurofibromatose 2/patologia , Neurofibromatose 2/fisiopatologia , Estudos Prospectivos , Serina-Treonina Quinases TOR/antagonistas & inibidores , Serina-Treonina Quinases TOR/metabolismo , Resultado do Tratamento , Carga Tumoral , Doenças do Nervo Vestibulococlear/patologia , Doenças do Nervo Vestibulococlear/fisiopatologia , Adulto JovemRESUMO
A 52-year-old man with a history of malignant lymphoma of the cecum presented with lancinating facial pain in the left. Magnetic resonance imaging (MRI) revealed a tumor in the Meckel's cave extending along the trigeminal nerve. The tumor was partially removed via left retrosigmoid lateral suboccipital craniotomy. Histological examination showed findings consistent with diffuse large B cell lymphoma, which was later confirmed to be metastatic lesion from the cecal lesion. Postoperative chemotherapy with cyclophosphamide, high dose, cytarabine, steroid (dexamethasone), etoposide, and rituximab (CHASER) followed by whole brain irradiation (30 Gy) resulted in complete remission. Although facial pain persisted, the patient's general condition remained favorable and he did not experience recurrence over the 51-month follow-up period. Histological confirmation and awareness of malignant lymphoma are very important to determine the therapeutic strategy and to avoid misdiagnosis or delayed diagnosis. Long-term survival of patients with metastatic malignant lymphoma in the Meckel's cave extending along the trigeminal nerve was very rare. In addition, metastatic malignant lymphoma in the extra-axial and peripheral nervous tissue might be different from primary central nervous system lymphoma in the white matter, since the efficacy of chemotherapeutic agents against malignant lymphomas in the extra-axial regions is not attenuated by the blood brain barrier.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Ceco/tratamento farmacológico , Neoplasias do Ceco/patologia , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/patologia , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/patologia , Rituximab/administração & dosagem , Sobreviventes , Doenças do Nervo Trigêmeo/tratamento farmacológico , Doenças do Nervo Trigêmeo/patologia , Neoplasias do Ceco/diagnóstico , Quimioterapia Adjuvante , Terapia Combinada , Neoplasias dos Nervos Cranianos/diagnóstico , Ciclofosfamida/uso terapêutico , Citarabina/uso terapêutico , Dexametasona/uso terapêutico , Etoposídeo/uso terapêutico , Humanos , Linfoma Difuso de Grandes Células B/diagnóstico , Masculino , Pessoa de Meia-Idade , Doenças do Nervo Trigêmeo/diagnósticoRESUMO
OBJECT: Malignant peripheral nerve sheath tumors (MPNSTs) are a rare form of malignancy arising from the Schwann cells of peripheral nerves. MPNSTs of the trigeminal nerve are exceptionally rare, with only a handful of reports in the literature. These tumors are typically very aggressive, resulting in significant patient morbidity and a generally grim prognosis. Most current reports suggest that radical resection with radiation therapy offers the best benefit. In this study, the authors systematically reviewed the world English-language literature on MPNSTs of the trigeminal nerve to analyze the presentations, treatment options, and outcomes for patients with this disease. METHODS: A literature search for MPNSTs of the trigeminal nerve confined to nonanimal, English-language articles was conducted utilizing the PubMed database, with additional cases chosen from the references of selected articles. Only cases of confirmed MPNSTs of the trigeminal nerve or its peripheral branches, based upon surgical, pathological, or radiological analysis, were included. RESULTS: From the literature search, 29 articles discussing 35 cases of MPNSTs of the trigeminal nerve were chosen. With the addition of 1 case from their own institution, the authors analyzed 36 cases of trigeminal MPNSTs. The average age of onset was 44.6 years. These tumors were more commonly seen in male patients (77.1%). The gasserian ganglion was involved in 36.1% of the cases. Of the cases in which the nerve distribution was specified (n = 25), the mandibular branch was most commonly involved (72.0%), followed by the maxillary branch (60.0%) and the ophthalmic branch (32.0%), with 44.0% of patients exhibiting involvement of 2 or more branches. Altered facial sensation and facial pain were the 2 most commonly reported symptoms, found in 63.9% and 52.8% of patients, respectively. Mastication difficulty and diplopia were seen in 22.2% of patients, facial weakness was seen in 19.4%, and hearing loss was present in 16.7%. With regard to the primary treatment strategy, 80.6% underwent resection, 16.7% underwent radiation therapy, and 2.9% received chemotherapy alone. Patients treated with complete resection followed by postoperative radiation therapy had the most favorable outcomes, with no patients showing evidence of disease recurrence with a mean follow-up of 34.6 months. Patients treated with incomplete resection followed by postoperative radiation therapy had more favorable outcomes than patients treated with incomplete resection without radiation therapy or radiation therapy alone. CONCLUSIONS: Trigeminal MPNSTs most commonly present as altered facial sensation or facial pain, although they exhibit a number of other clinical manifestations, including the involvement of other cranial nerves. While a variety of treatment options exist, due to their highly infiltrative nature, aggressive resection followed by radiation therapy appears to offer the greatest chance of recurrence-free survival.
Assuntos
Neoplasias dos Nervos Cranianos/cirurgia , Neoplasias de Bainha Neural/cirurgia , Doenças do Nervo Trigêmeo/cirurgia , Adolescente , Adulto , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Criança , Terapia Combinada , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/epidemiologia , Neoplasias dos Nervos Cranianos/patologia , Neoplasias dos Nervos Cranianos/radioterapia , Diplopia/etiologia , Neuralgia Facial/etiologia , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Neoplasias de Bainha Neural/tratamento farmacológico , Neoplasias de Bainha Neural/epidemiologia , Neoplasias de Bainha Neural/patologia , Neoplasias de Bainha Neural/radioterapia , Neurocirurgia/métodos , Prognóstico , Radioterapia Adjuvante , Resultado do Tratamento , Doenças do Nervo Trigêmeo/tratamento farmacológico , Doenças do Nervo Trigêmeo/epidemiologia , Doenças do Nervo Trigêmeo/patologia , Doenças do Nervo Trigêmeo/radioterapia , Adulto JovemRESUMO
Despite a high proportion of patients with primary CNS lymphoma (PCNSL) experiences failure after/during first-line treatment, a few studies focused on salvage therapy are available, often with disappointing results. Herein, we report feasibility and activity of a combination of rituximab, ifosfamide and etoposide (R-IE regimen) in a multicentre series of patients with PCNSL relapsed or refractory to high-dose methotrexate-based chemotherapy. We considered consecutive HIV-negative patients ≤75 years old with failed PCNSL treated with R-IE regimen (rituximab 375 mg/m(2) , day 0; ifosfamide 2 g/m(2) /day, days1-3; etoposide 250 mg/m(2) , day 1; four courses). Twenty-two patients (median age 60 years; range 39-72; male/female ratio: 1:4) received R-IE as second-line (n = 18) or third-line (n = 4) treatment. Eleven patients had refractory PCNSL, and 11 had relapsing disease. Twelve patients had been previously irradiated. Sixty (68%) of the 88 planned courses were actually delivered; only one patient interrupted R-IE because of toxicity. Grade 4 hematological toxicity was manageable; a single case of grade 4 non-hematological toxicity (transient hepatotoxicity) was recorded. Response was complete in six patients and partial in three (overall response rate = 41%; 95%CI: 21-61%). Seven patients were successfully referred to autologous peripheral blood stem cell collection; four responders were consolidated with high-dose chemotherapy supported by autologous stem cell transplant. At a median follow-up of 24 months, eight responders did not experience relapse, two of them died of neurological impairment while in remission. Six patients are alive, with a 2-year survival after relapse of 25 ± 9%. We concluded that R-IE is a feasible and active combination for patients with relapsed/refractory PCNSL. This regimen allows stem cell collection and successful consolidation with high-dose chemotherapy and autologous transplant.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias do Sistema Nervoso Central/tratamento farmacológico , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Terapia de Salvação , Idoso , Anticorpos Monoclonais Murinos/administração & dosagem , Anticorpos Monoclonais Murinos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias do Sistema Nervoso Central/radioterapia , Neoplasias do Sistema Nervoso Central/cirurgia , Terapia Combinada , Irradiação Craniana , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/radioterapia , Neoplasias dos Nervos Cranianos/cirurgia , Esquema de Medicação , Avaliação de Medicamentos , Resistencia a Medicamentos Antineoplásicos , Etoposídeo/administração & dosagem , Etoposídeo/efeitos adversos , Neoplasias Oculares/tratamento farmacológico , Neoplasias Oculares/radioterapia , Neoplasias Oculares/cirurgia , Feminino , Seguimentos , Transplante de Células-Tronco Hematopoéticas , Humanos , Ifosfamida/administração & dosagem , Ifosfamida/efeitos adversos , Estimativa de Kaplan-Meier , Linfoma Difuso de Grandes Células B/radioterapia , Linfoma Difuso de Grandes Células B/cirurgia , Masculino , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Transplante de Células-Tronco de Sangue Periférico , Recidiva , Indução de Remissão , Estudos Retrospectivos , Rituximab , Análise de Sobrevida , Transplante Autólogo , Resultado do TratamentoRESUMO
BACKGROUND: Cranial nerve palsies has several etiologies including vascular insufficiency, neoplasm, trauma and inflammation. Isolated sixth nerve palsy is an extremely rare presenting feature of leukemia. AIM: We describe an unusual ocular presentation of a bilateral progressive sixth nerve palsy in a young male with a preceding head injury. CONCLUSION: Acquired sixth nerve palsies in young adults may be due to trauma but in the absence of a definitive history other systemic processes must be outruled. We describe a case of bilateral sixth nerve palsy in a patient with ALL with no obvious CNS involvement. Potential etiological mechanisms are discussed.
Assuntos
Doenças do Nervo Abducente/diagnóstico , Neoplasias dos Nervos Cranianos/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Doenças do Nervo Abducente/patologia , Adolescente , Antineoplásicos/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/patologia , Humanos , Pressão Intracraniana , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Síndrome da Veia Cava Superior , Disparidade VisualAssuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias Faciais/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Doenças do Nervo Trigêmeo/tratamento farmacológico , Idoso , Carboplatina/administração & dosagem , Carcinoma de Células Escamosas/patologia , Bochecha , Neoplasias dos Nervos Cranianos/patologia , Neoplasias Faciais/patologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Invasividade Neoplásica , Recidiva Local de Neoplasia/patologia , Paclitaxel/administração & dosagem , Doenças do Nervo Trigêmeo/patologiaAssuntos
Neoplasias Encefálicas/secundário , Carcinoma de Células Pequenas/secundário , Neoplasias dos Nervos Cranianos/secundário , Nervo Facial/patologia , Neoplasias Pulmonares/patologia , Antineoplásicos Hormonais/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/radioterapia , Carcinoma de Células Pequenas/tratamento farmacológico , Carcinoma de Células Pequenas/radioterapia , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/radioterapia , Dexametasona/uso terapêutico , Evolução Fatal , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Imageamento por Ressonância Magnética , Pessoa de Meia-IdadeAssuntos
Neoplasias dos Nervos Cranianos/patologia , Linfoma de Células B/patologia , Adolescente , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Humanos , Linfoma de Células B/tratamento farmacológico , Imageamento por Ressonância Magnética , Masculino , Prednisona/administração & dosagem , Vincristina/administração & dosagemAssuntos
Antineoplásicos Hormonais/uso terapêutico , Neoplasias dos Nervos Cranianos/secundário , Diplopia/etiologia , Hormônio Liberador de Gonadotropina/análogos & derivados , Neoplasias da Próstata , Idoso , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Diplopia/tratamento farmacológico , Humanos , MasculinoAssuntos
Neoplasias dos Nervos Cranianos/patologia , Leucemia Mieloide Aguda/patologia , Infiltração Leucêmica , Doenças do Nervo Óptico/patologia , Neoplasias Cutâneas/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Doenças do Nervo Óptico/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
BACKGROUND: Extra-axial primary CNS lymphoma, considered rare, mainly arise in the white matter of the brain. Though the tumor responds well to radiation and chemotherapy, the prognosis of primary CNS lymphoma remains poor. We report a case of primary lymphoma of Meckel's cave mimicking a trigeminal schwannoma radiographically, which achieved complete remission through use of rapid high-dose MTX therapy and radiation therapy. CASE DESCRIPTION: The patient, a 55-year-old Japanese male, presented left trigeminal neuralgia. Magnetic resonance imaging (MRI) revealed a mass lesion in the left side of Meckel's cave, with extension into the cerebellopontine angle and the infratemporal fossa through the foramen ovale, suggesting trigeminal schwannoma. However, the patient suffered radiologically inexplicable progressive cranial nerve palsy, which suggested malignant disease. MRI and CSF disclosed malignant tumor dissemination; biopsy revealed malignant lymphoma. The treatment, composed of the rapid infusion of high-dose MTX and whole brain and spine radiation, resulted in complete remission. CONCLUSIONS: This case, which included atypical presentation of malignant lymphoma, illustrates the importance of including malignant lymphoma in the differential diagnosis of CP-angle and Meckel's cave tumor. The results also confirmed the usefulness of combined rapid high-dose MTX therapy and radiation.
Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/radioterapia , Linfoma/tratamento farmacológico , Linfoma/radioterapia , Metotrexato/administração & dosagem , Doenças do Nervo Trigêmeo/tratamento farmacológico , Doenças do Nervo Trigêmeo/radioterapia , Neuralgia do Trigêmeo/etiologia , Quimioterapia Adjuvante , Irradiação Craniana , Neoplasias dos Nervos Cranianos/complicações , Esquema de Medicação , Humanos , Infusões Intravenosas , Linfoma/complicações , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Radioterapia Adjuvante , Coluna Vertebral/efeitos da radiação , Resultado do Tratamento , Doenças do Nervo Trigêmeo/complicaçõesRESUMO
Leptomeningeal metastases (LMs) are common metastatic complications, occurring in at least 5% of patients with disseminated cancer. Cerebrospinal fluid (CSF) cytology remains the standard for diagnosis and assessment of treatment response, but may be inadequate. Our objective was to compare ventricular and lumbar CSF cytology in patients who had cytologically proven LM and were receiving intra-CSF chemotherapy. Sixty patients with LM, positive lumbar CSF cytology documented at diagnosis, limited extent of CNS disease, and no evidence of CSF flow obstruction were treated with a variety of intra-CSF chemotherapies. All patients underwent a single simultaneous ventricular and lumbar CSF sampling (mean volume of CSF per site examined, 10 ml) to assess response to therapy at either 1 or 2 months after treatment initiation. Ventricular CSF cytology was positive in 44 patients (73%), 35 of whom were also positive by lumbar CSF cytology. Lumbar CSF cytology was positive in 45 patients (75%), of which 35 were also positive by ventricular CSF cytology. Samples were negative at both ventricular and lumbar sites in 6 patients (10%). Paired CSF cytologies were discordant in 19 (32%) patients. The lumbar cytology was negative in 9, whereas the ventricular cytology was positive (lumbar false-negative rate of 17%); the ventricular cytology was negative in 10, whereas the lumbar cytology was positive (ventricular false-negative rate of 20%). In the presence of spinal signs or symptoms of LM, the lumbar CSF cytology was more likely to be positive than was the ventricular (odds ratio = 2.86; 95% confidence interval, 0.86-9.56). Conversely, in the presence of cranial signs or symptoms, the ventricular CSF cytology was more likely to be positive than was the lumbar (odds ratio = 2.71; 95% confidence interval, 0.76-9.71). In this cohort of patients, whose LM was documented initially by positive lumbar CSF cytology, ventricular and lumbar CSF samples obtained during treatment had similar false-negative rates, depending on the site of clinical or radiologic disease. This suggests that both lumbar and ventricular sites must be sampled when assessing treatment response. If clinical or radiographic disease is present only at 1 site, then CSF from that site is more likely to be positive than is CSF obtained from the more distant site.
Assuntos
Neoplasias Encefálicas/secundário , Ventrículos Cerebrais/patologia , Líquido Cefalorraquidiano/citologia , Neoplasias Meníngeas/secundário , Neoplasias da Coluna Vertebral/secundário , Punção Espinal , Adulto , Idoso , Idoso de 80 Anos ou mais , Antineoplásicos/administração & dosagem , Antineoplásicos/uso terapêutico , Neoplasias Encefálicas/líquido cefalorraquidiano , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias dos Nervos Cranianos/líquido cefalorraquidiano , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/secundário , Reações Falso-Negativas , Feminino , Humanos , Injeções Intraventriculares , Masculino , Neoplasias Meníngeas/líquido cefalorraquidiano , Neoplasias Meníngeas/tratamento farmacológico , Pessoa de Meia-Idade , Células-Tronco Neoplásicas/patologia , Especificidade de Órgãos , Estudos Retrospectivos , Neoplasias da Coluna Vertebral/líquido cefalorraquidiano , Neoplasias da Coluna Vertebral/tratamento farmacológico , Resultado do TratamentoRESUMO
Involvement of the cavernous sinus region due to haematogenous spread or by local extension of a malignant head and neck tumour does not occur frequently. Six patients were treated by external beam radiation with (n=3) or without neoadjuvant chemotherapy between December 1989 and February 1996. Manifestations of the condition mainly consisted of fifth and sixth cranial nerve deficits (n=4). Complete resolution of cranial nerve deficits after therapy occurred in two of the four patients with only three individuals having been evaluable. Three of the six patients survived for more than 3 years. Thus, palliation can be achieved by chemoradiation or radiotherapy alone, and long term survival is not precluded.
Assuntos
Seio Cavernoso , Neoplasias dos Nervos Cranianos/secundário , Cuidados Paliativos , Neoplasias Cranianas/secundário , Neoplasias Cranianas/terapia , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/patologia , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/radioterapia , Carcinoma de Células Escamosas/secundário , Carcinoma de Células Escamosas/terapia , Quimioterapia Adjuvante , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/radioterapia , Neoplasias dos Nervos Cranianos/terapia , Feminino , Humanos , Masculino , Neoplasias do Seio Maxilar/patologia , Pessoa de Meia-Idade , Neoplasias Nasofaríngeas/patologia , Neoplasias da Próstata/patologia , Estudos Retrospectivos , Neoplasias Cranianas/tratamento farmacológico , Neoplasias Cranianas/radioterapiaRESUMO
We report a rare primary intracranial malignant lymphoma which spread along the trigeminal nerve through the skull base foramen. The patient was a 50-year-old woman, who was diagnosed as having a primary intracranial malignant lymphoma in the right temporal lobe and had undergone an operation and radiation 5 years previously. The tumor was reduced in size and no recurrent tumor could be detected for 5 years. The patient complained of left face swelling and CT scan revealed a large mass in the pterygopalatine fossa. MRI revealed the recurrent tumor in the left Meckel's cave with extension into the cavernous sinus. The tumor extended through the foramen ovale into the pterygopalatine fossa, through the superior orbital fissure into the orbital cavity and through the infraorbital fossa into the face subcutaneously. Biopsy of the subcutaneous tumor was carried out and the pathological diagnosis was malignant lymphoma, B cell type, which was identical with the initial tumor. MRI revealed the enlarged trigeminal nerve and 3D-CT revealed the enlargement of the infraorbital fossa and the foramen ovale. We suspected that primary intracranial malignant lymphoma had recurred in the left Meckel's cave and the tumor had spread along the peripheral three divisions of the trigeminal nerve. Perineural spreading along the trigeminal nerve passing through the skull base in patients with nasopharyngeal carcinoma is not rare, but this rarely occurs in the case of intracranial tumors.
Assuntos
Neoplasias Encefálicas/patologia , Neoplasias dos Nervos Cranianos/patologia , Linfoma de Células B/patologia , Nervo Trigêmeo/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Encefálicas/tratamento farmacológico , Seio Cavernoso , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Ciclofosfamida/administração & dosagem , Doxorrubicina/administração & dosagem , Feminino , Humanos , Linfoma de Células B/tratamento farmacológico , Pessoa de Meia-Idade , Invasividade Neoplásica , Prednisolona/administração & dosagem , Resultado do Tratamento , Vincristina/administração & dosagemRESUMO
BACKGROUND: The authors discuss the local pharmacotherapy for chronic orofacial neuropathic pain disorders such as neuropathies, neuromas and neuralgias. METHODS: The authors conducted a systematic literature review on this topic. The focus of the review involved the two most commonly applied medications for neuropathic disorders--local anesthetics and capsaicin. Other compounds such as nonsteroidal anti-inflammatory drugs, sympathomimetic agents, anticonvulsants and N-methyl-D-aspartate receptor antagonists also were reviewed. The medication delivery and retention methods appropriate for oral and perioral disease and pain control are described in this article. RESULTS: There are an ever-increasing number of agents that can be used to help patients with neuropathic-based oral and perioral pain problems. Moreover, a clear advancement in the delivery of these medications is the development of a vehicle-carrier agent (pluronic lecithin organogel) that can penetrate the mucosa and cutaneous tissues and carry the active medication with it to the treatment site. The major caveat underlying these treatment strategies is that except for patient testimony and a few studies, there are limited empirical data on the efficacy of most of these new formulations, and additional research is clearly needed. CONCLUSIONS: Because of their rapid onset and low side-effect profile, topical medications offer a distinct advantage over systemic administration for those orofacial disorders that are regional, near the surface and chronic and that demonstrate some response such as pain relief to topical or subcutaneous anesthetics. CLINICAL IMPLICATIONS: Practicing dentists now have some new tools they can use to help manage patients who have a chronic nerve pain disorder in and around the mouth.
Assuntos
Analgésicos/uso terapêutico , Doenças dos Nervos Cranianos/tratamento farmacológico , Dor Facial/tratamento farmacológico , Administração Tópica , Analgésicos/administração & dosagem , Anestésicos Locais/administração & dosagem , Anestésicos Locais/uso terapêutico , Capsaicina/administração & dosagem , Capsaicina/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Portadores de Fármacos , Sistemas de Liberação de Medicamentos , Humanos , Neuralgia/tratamento farmacológico , Neuroma/tratamento farmacológico , FosfatidilcolinasRESUMO
Management of low grade optic glioma in children and adolescents remains controversial. Treatment with chemotherapy may delay or eliminate the need for radiation therapy. Children with newly diagnosed optic chiasm glioma were eligible for enrollment in this phase II trial and received intravenous carboplatin (CBDCA) (560 mg/m2) every four weeks. Patients were monitored closely for toxicity and tumor status. Twelve children were enrolled. Six patients had stable disease, four a partial response and two progressed on therapy. Overall progression free survival was 83 +/- 11%. The median duration of follow-up was 38.6 months (range 18-63 months). No deaths were noted in our series. Thrombocytopenia was the major toxicity, and two patients required platelet transfusions. One child developed an urticarial reaction requiring discontinuation of therapy. Another child developed unilateral high frequency hearing loss. No renal toxicity was encountered. We have demonstrated that carboplatin can eliminate or delay radiation therapy in children and adolescents with low grade optic glioma. CBDCA deserves further investigation in larger clinical trials as a treatment for children with optic chiasm glioma.
Assuntos
Antineoplásicos/uso terapêutico , Carboplatina/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Glioma/tratamento farmacológico , Quiasma Óptico , Adolescente , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Carboplatina/administração & dosagem , Carboplatina/efeitos adversos , Criança , Pré-Escolar , Neoplasias dos Nervos Cranianos/mortalidade , Neoplasias dos Nervos Cranianos/patologia , Intervalo Livre de Doença , Esquema de Medicação , Feminino , Glioma/mortalidade , Glioma/patologia , Humanos , Lactente , Infusões Intravenosas , Imageamento por Ressonância Magnética , Masculino , Taxa de Sobrevida , Fatores de TempoRESUMO
BACKGROUND: Corticosteroids are frequently used for the prevention and treatment of neural edema. Although perioperative steroid therapy has been used in patients undergoing acoustic neuroma removal, the efficacy of such therapy has not been previously documented. METHODS: A retrospective review of 169 patients who underwent acoustic neuroma surgery with (n = 75) or without (n = 94) a single dose of intraoperative corticosteroids was performed. Tumor size ranged from 0.4 cm to 6 cm (mean, 2.1; SD, 1.0) The translabyrinthine approach was used in 85% of the patients, and the middle cranial fossa approach was used in 13%. Data were analyzed for differences in postoperative facial function and complication rates. RESULTS: After controlling for differences in tumor size, no significant effects of steroid therapy were found for any of the outcome variables. CONCLUSIONS: This retrospective study showed no apparent benefit from intraoperative steroid use in acoustic neuroma surgery. A prospective, randomized, placebo-controlled trial should be performed to confirm these findings.
Assuntos
Anti-Inflamatórios/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Dexametasona/uso terapêutico , Monitorização Intraoperatória , Neuroma Acústico/tratamento farmacológico , Anti-Inflamatórios/farmacologia , Dexametasona/farmacologia , Relação Dose-Resposta a Droga , Nervo Facial/efeitos dos fármacos , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/diagnóstico , Estudos RetrospectivosRESUMO
Symptomatic optic pathway tumors (OPT) occur in 7% of children with neurofibromatosis type-1 (NF-1). Although tumor progression following diagnosis is unusual in such children, specific therapy may be necessary for patients with either severe or progressive disease. We reviewed the records of 9 children (6 girls, 3 boys) with NF-1 associated OPT who were treated with the second generation platinum compound carboplatin. Carboplatin was given at a dose of 560 mg/mm2 every 4 weeks for a mean of 15 cycles. The mean age at presentation of the OPT was 3.4 years. Eight children had abnormal ophthalmologic examinations at the time of diagnosis. Only 4 patients had documented evidence of progressive disease prior to the institution of therapy. No patient had evidence of progressive disease following therapy. Four patients had radiologic evidence of tumor shrinkage and 2 patients had definite improvement in vision. There was only minimal toxicity. In conclusion, carboplatin is a safe and effective treatment for OPT in children with NF-1. However, as disease stabilization of NF-1 associated OPT often occurs following clinical presentation, the clinician should document tumor progression or visual deterioration prior to the institution of therapy.
Assuntos
Antineoplásicos/uso terapêutico , Carboplatina/uso terapêutico , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neurofibromatose 1/tratamento farmacológico , Nervo Óptico , Criança , Pré-Escolar , Feminino , Seguimentos , Humanos , Lactente , Masculino , Estudos Retrospectivos , Fatores de TempoRESUMO
The authors cared for a patient suffering from left trigeminal neuralgia who had systemic malignant lymphoma which had been treated with chemotherapy. The lesion of the left trigeminal nerve was not detected by brain CT scans or by the magnetic resonance images made at the onset of trigeminal neuralgia. However, metastasis to the left trigeminal nerve root was disclosed 6 months after the onset of the systemic lymphoma. Open biopsy confirmed lymphomatous involvement of the left trigeminal nerve root. In this case the site of the metastasis was mainly the trigeminal nerve root entry zone in the cerebellopontine cistern, and the lesion caused left trigeminal neuralgia and sensory impairment.
Assuntos
Neoplasias dos Nervos Cranianos/complicações , Linfoma Difuso de Grandes Células B/complicações , Nervo Trigêmeo , Neuralgia do Trigêmeo/etiologia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Terapia Combinada , Neoplasias dos Nervos Cranianos/tratamento farmacológico , Neoplasias dos Nervos Cranianos/cirurgia , Citarabina/administração & dosagem , Gadolínio DTPA , Humanos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/cirurgia , Imageamento por Ressonância Magnética , Masculino , Mitoxantrona/administração & dosagem , Prednisolona/administração & dosagem , Neuralgia do Trigêmeo/diagnóstico , Neuralgia do Trigêmeo/radioterapiaRESUMO
PURPOSE: In children with chiasmal gliomas, radiation therapy can arrest progressive visual and neurologic impairment. We examined the radiographic response and clinical outcomes after irradiation. METHODS AND MATERIALS: Forty-two children (median age at diagnosis, 6.6 years) with chiasmal gliomas were managed as follows: 11 asymptomatic patients with neurofibromatosis-1 (NF-1) were observed only; 2 patients, less than 3 years old, underwent surgery and chemotherapy to delay irradiation; and 29 patients with progressive disease received radiation with or without prior surgery or chemotherapy. Time to radiographic response, long-term tumor control and late sequelae were reviewed for the 29 irradiated patients. RESULTS: The probability of at least 50% radiographic response at 24 months after irradiation was 18.1% and increased to 38.2% by 48 months and 45.9% by 60 months. By actuarial analysis, the median time for such radiographic response was 62 months. For the 29 irradiated patients, the 10-year freedom from progression and overall survival rates were 100% and 89%, respectively (median follow-up for surviving patients, 108 months). Stabilization or improvement in vision occurred in 81% of 26 evaluable irradiated patients. CONCLUSIONS: Notable radiographic response may be observed years after irradiation. Radiation therapy provides excellent long-term tumor control and vision preservation or improvement in the majority of patients with progressive chiasmal gliomas.